PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Regulation FD Disclosure

PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Robert Overell, Ph.D., president and chief executive of PhaseRx, Inc. (the “Company”), will present on November 1, 2017, at the 5th International mRNA Health Conference, taking place from November 1 to November 2, 2017, in Berlin, Germany.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On October 31, 2017, the Company issued a press release announcing that Dr. Overell will give a presentation on the development of the Company’s mRNA therapeutic, PRX-OTC, to treat ornithine transcarbamylase deficiency at the 5th International mRNA Health Conference. A copy of such press release is attached hereto as Exhibit 99.2 and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


PHASERX, INC. Exhibit
EX-99.1 2 tv478117_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Unlocking the value of mRNA ® m RNA THERAPEUTICS FOR UREA CYCLE DISORDERS 5 th International mRNA Conference November 1 – 2,…
To view the full exhibit click here

About PhaseRx, Inc. (NASDAQ:PZRX)

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

An ad to help with our costs